21 May 2009
CTX-M and tem as a predominant type of extended spectrum beta-lactamase among serratia marcescens isolated from solid organ recipients
A Młynarczyk, K Szymanek, A Sawicka-Grzelak, J Pazik, T Buczkowska, M Durlik, B Łągiewska, M Pacholczyk, A Chmura, L Pączek, G MłynarczykAnn Transplant 2009; 14(1): 71-71 :: ID: 880461
Abstract
Background: Serratia marcescens is an important pathogen in hospital infections, especially among patients with impaired immunity. Particularly dangerous are strains producing extended - spectrum beta - lactamases (ESBLs) and carbapenemases. The aim of the work was to establish the percentage of ESBL producing strains of S. marcescens isolated form patients of Transplantation Institute of Transplantology as well as the type of the enzyme.
Material/Methods: The standard clinical microbiology methods were applied to identification and assessment antibiotics susceptibility of S. marcescens isolated from patients of Institute of Transplantology in four years (2005-2008). All strains were examined for ESBL production by several phenotype methods. 28 strains were examined in PCR reaction with starters for most popular types of ESBLs: TEM, SHV, CTX-M.
Results: In total 386 S. marcescens strains from 257 patients were isolated from various specimens form patients from Transplantation Institute. In 2005, 88 patients were infected, and respectively in 2006, 82 patients, in 2007, 57 patients and in 2008, 30. In the case of 188 patients (73%), it was shown by phenotype methods that infecting strain produced ESBL. From 28 strains chosen for molecular analysis 17 produced both CTX-M and TEM beta-lacta-mase, 9 produced only TEM - type, and 2 strains only CTX-M type beta-lacta-mase. Two strains from 2008 were resistant to carbapenems.
Conclusions: In the 2008 the frequency of S. marcescens isolation diminished two times compared to the previous years. The CTX-M-type of ESBL predominated among beta-lactamases produced by the strains. Alarming is the appearance of S. marcescens strains resistant to carbapenems.
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588






